Author: Basamat Almoallem (Saudi Arabia)
Co-authors: Manar Aoun
Purpose
Inherited retinal diseases (IRDs) represent a heterogeneous group of rare visually debilitating diseases that are caused by mutations in over 300 critical genes for retinal function. Overall, the clinical diagnosis of IRDs is challenging due to several levels of complexity, including locus and allelic heterogeneity with variable expression. Therefore, reporting the precise phenotype with optimum genetic testing selection is critical to confirm clinical diagnosis and build up a genotype-phenotype correlation.
Setting/Venue
An ophthalmological clinical setting optimized to precisely diagnose IRD cases.
Methods
Molecular diagnosis is needed to provide a complete and comprehensive clinical diagnosis of IRDs; this requires a multidisciplinary team including an IRD specialist and a molecular geneticist, bioinformatician, clinical scientist, and genetic counselor. This has resulted in an impressive database of families with phenotypic information under the umbrella of IRDs in which state-of the-art recent molecular techniques are applied to deliver a precise diagnosis. A detailed ophthalmological examination, including best-corrected visual acuity, refraction, slit-lamp examination, fundus imaging, optical coherence tomography, and assessment of electrophysical functions of the entire retina by full-field electroretinography is mandatory to obtain a clear phenotype. Clinical examinations should be followed by selecting the best genetic testing strategy and genetic sequencing tool for a given patient by opting for one of the advanced molecular techniques including clinically-oriented gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS). An understanding of the capabilities and limitations of each modality is necessary, with harmonization between the multidisciplinary team to resolve cases with inconclusive data, such as variants of uncertain significance, missing heritability, or novel findings.
Results
The clinical diagnosis of IRDs alone is considered to be incomplete according to American Association of Ophthalmology (AAO) guidelines. This fact relies on the principle that the ophthalmological examination is largely unremarkable; this leads to a dilemma of frequent referral by a non-expert in IRDs. To date, the AAO has listed genetic testing as an integral component for diagnosing IRD cases; this creates a paradigm shift in diagnostic rates. Success relies on the application of clinically-oriented gene panels, WES, and WGS leading to the identification of disease-causing mutations in known and novel genes. Nowadays, most genetic laboratories are applying a uniform classification system of 5 classes to rank the pathogenicity of identified variants based on American College of Medical Genetics guidelines: (1: pathogenic, 2: likely pathogenic, 3: unknown significance, 4: likely benign, and 5: benign). Variants ranked as 1 or 2 can be reported with genotype-phenotype correlation. Variants with class 4 or 5 should not be considered resolved and require further review to upgrade the genetic testing. The most challenging category is class 3 of inconclusive data that requires further research collaboration and close follow-up of the various databases.
Conlusions
Given the advantage of the eye with its anatomically and immunologically preserved structure, approximately 30 ongoing gene therapy-based clinical trials are being conducted worldwide applying different molecular techniques aimed at target IRD genes and variants. Establishing the correlation between genotype and phenotype is mandatory in the diagnosis of IRDs. The resulting diagnostic yields from genetic testing approaches and resolution of cases with inconclusive data, such as variants of unknown significance (VUS) are applied to serve the goal of precision medicine and will help to translate these findings into proof-of-concept clinical trials and enhance the enrolment of all targeted patients in ongoing worldwide therapeutic interventions.
Financial Disclosure
Dr. Basamat Almoallem has nothing to disclose; Dr. Manar Aoun is an employee of Novartis Pharmaceuticals, Italy.
Comments
-